LL-37 (Human Cathelicidin) is the C-terminal, active form of the human cathelicidin (hCAP18). It exhibits broad-spectrum antimicrobial activity and immunomodula…
Half-life
Short; rapidly degraded by proteases (minutes in biological fluids), context-dependent with topical matrices potentially prolonging effect
Delivery
Primarily topical or localized/intradermal application in research; formulations often use gels, creams, or hydrogel dressings to improve stability and retention.
Suggested dosage
Not specified
Usage
Mechanism of action
Benefits (4)
- Broad-spectrum antimicrobial and anti-biofilm activity
- Supports wound closure and re-epithelialization
- Enhances local immune surveillance and barrier function
- LPS neutralization and modulation of inflammatory signaling
Side effects (4)
- Local irritation, burning, or erythema at application site
- Pro-inflammatory effects at higher concentrations
- Potential flare of inflammatory dermatoses (e.g., psoriasis models)
- Rare hypersensitivity reactions